Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Clostridium septicum alpha-toxin is a potent, pore-forming exotoxin and the primary virulence factor of the gram-positive bacterium Clostridium septicum (Kennedy et al., 2005, PubMed: 15805227). It is synthesized as an inactive 51 kDa protoxin that requires proteolytic cleavage of a C-terminal peptide, typically by host cell furin, to become active (Gordon et al., 1997, PubMed: 9351814). Once activated, the toxin binds with high affinity to glycosylphosphatidylinositol (GPI)-anchored proteins, such as CD59, on the surface of host cells, where it oligomerizes to form heptameric pores (Knapp et al., 2010, PubMed: 20083661). These pores disrupt the plasma membrane's integrity, leading to rapid efflux of potassium ions, influx of calcium, and eventual cell death through necrosis or apoptosis. Clinically, this toxin is the driving force behind spontaneous gas gangrene (myonecrosis), a condition characterized by rapid tissue destruction and high mortality, often occurring in patients with underlying immunosuppression or gastrointestinal malignancies (Stevens & Bryant, 2017, StatPearls). Therapeutic strategies focus on neutralizing the toxin using antitoxins and suppressing its production through protein-synthesis-inhibiting antibiotics like clindamycin (PubMed: 28603331).
Neutralization of the toxin by specific antibodies to prevent binding to host cell receptors and subsequent pore formation (StatPearls, 2023).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Clostridium septicum alpha-toxin (ATX).